Literature DB >> 28565798

PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.

Xiaohui Xu1,2, Yushang Cui1,2, Lei Cao1,2, Ye Zhang1,2, Yan Yin1,2, Xue Hu1,2.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of PCs that encodes a neural apoptosis-regulated convertase 1. However, the precise role of PCSK9 in lung cancer cell apoptosis has remained elusive. In the present study, A549 human lung adenocarcinoma cells were transfected with PCSK9 small interfering (si)RNA to investigate the underlying mechanisms of apoptosis. The results indicated that PCSK9 siRNA exhibited anti-tumor activity by inducing apoptosis as determined by a Cell Counting Kit-8 and Hoechst staining analysis. In addition, PCSK9 siRNA significantly increased apoptosis of A549 cells in part via activation of caspase-3 and downregulation of the anti-apoptotic proteins survivin and X-linked inhibitor of apoptosis protein. Moreover, the results demonstrated that perturbations in the mitochondrial membrane were associated with the deregulation of the Bax/Bcl-2 ratio, which led to the release of cytochrome c after PCSK9 siRNA transfection. In addition, PCSK9 siRNA also induced endoplasmic reticulum stress (ERS) by increasing the levels of 78 kDa glucose-regulated protein (GRP78), GRP94, phosphorylated protein kinase R-like ER kinase and phosphorylated eukaryotic initiation factor 2α. Therefore, these results demonstrated that PCSK9 siRNA may exert its anti-tumor activity through inducing mitochondrial dysfunction and ERS-associated cell death in A549 cells.

Entities:  

Keywords:  PCSK9; apoptosis; endoplasmic reticulum stress; lung adenocarcinoma; mitochondrial dysfunction

Year:  2017        PMID: 28565798      PMCID: PMC5443240          DOI: 10.3892/etm.2017.4218

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

Review 1.  Mediators of endoplasmic reticulum stress-induced apoptosis.

Authors:  Eva Szegezdi; Susan E Logue; Adrienne M Gorman; Afshin Samali
Journal:  EMBO Rep       Date:  2006-09       Impact factor: 8.807

Review 2.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

Review 3.  Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.

Authors:  Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

4.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

5.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

6.  Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.

Authors:  Trine Ranheim; Morten Mattingsdal; Jessica M Lindvall; Oystein L Holla; Knut Erik Berge; Mari Ann Kulseth; Trond P Leren
Journal:  J Cell Physiol       Date:  2008-11       Impact factor: 6.384

Review 7.  IAP-targeted therapies for cancer.

Authors:  E C LaCasse; D J Mahoney; H H Cheung; S Plenchette; S Baird; R G Korneluk
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

8.  Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Authors:  Xiaowei Sun; Rachid Essalmani; Robert Day; Abdel M Khatib; Nabil G Seidah; Annik Prat
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

9.  Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.

Authors:  Simon R Stockwell; Georgina Platt; S Elaine Barrie; Georgia Zoumpoulidou; Robert H Te Poele; G Wynne Aherne; Stuart C Wilson; Peter Sheldrake; Edward McDonald; Mathilde Venet; Christelle Soudy; Frédéric Elustondo; Laurent Rigoreau; Julian Blagg; Paul Workman; Michelle D Garrett; Sibylle Mittnacht
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

Review 10.  Endoplasmic reticulum stress and apoptosis.

Authors:  Jitka Faitova; Daniel Krekac; Roman Hrstka; Borivoj Vojtesek
Journal:  Cell Mol Biol Lett       Date:  2006-09-05       Impact factor: 5.787

View more
  12 in total

Review 1.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

2.  Marine biogenics in sea spray aerosols interact with the mTOR signaling pathway.

Authors:  Jana Asselman; Emmanuel Van Acker; Maarten De Rijcke; Laurentijn Tilleman; Filip Van Nieuwerburgh; Jan Mees; Karel A C De Schamphelaere; Colin R Janssen
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 3.  Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9.

Authors:  Klaus-Dieter Schlüter; Annemarie Wolf; Rolf Schreckenberg
Journal:  Front Physiol       Date:  2020-12-07       Impact factor: 4.566

4.  PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.

Authors:  Shi-Zhe Zhang; Xiao-Dong Zhu; Long-Hai Feng; Xiao-Long Li; Xue-Feng Liu; Hui-Chuan Sun; Zhao-You Tang
Journal:  Exp Hematol Oncol       Date:  2021-03-31

5.  LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis.

Authors:  Xiangguang Shi; Yahui Chen; Qingmei Liu; Xueqian Mei; Jing Liu; Yulong Tang; Ruoyu Luo; Dayan Sun; Yanyun Ma; Wenyu Wu; Wenzhen Tu; Yinhuan Zhao; Weihong Xu; Yuehai Ke; Shuai Jiang; Yan Huang; Rui Zhang; Lei Wang; Yuanyuan Chen; Jingjing Xia; Weilin Pu; Honglin Zhu; Xiaoxia Zuo; Yisha Li; Jinhua Xu; Fei Gao; Dong Wei; Jingyu Chen; Wenguang Yin; Qingwen Wang; Huaping Dai; Libing Yang; Gang Guo; Jimin Cui; Nana Song; Hejian Zou; Shimin Zhao; Jörg H W Distler; Li Jin; Jiucun Wang
Journal:  Clin Transl Med       Date:  2022-01

6.  Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Authors:  Mengqing Xie; Xin Yu; Xiangling Chu; Huikang Xie; Juan Zhou; Jing Zhao; Chunxia Su
Journal:  Thorac Cancer       Date:  2021-12-27       Impact factor: 3.500

7.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25

Review 8.  Pleiotropic Effects of PCSK-9 Inhibitors.

Authors:  Marcin Basiak; Michał Kosowski; Marcin Cyrnek; Łukasz Bułdak; Mateusz Maligłówka; Grzegorz Machnik; Bogusław Okopień
Journal:  Int J Mol Sci       Date:  2021-03-19       Impact factor: 5.923

9.  Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway.

Authors:  Mingyan He; Jing Hu; Tingting Fang; Wenqing Tang; Bei Lv; Biwei Yang; Jinglin Xia
Journal:  Cancer Biol Med       Date:  2021-04-24       Impact factor: 4.248

10.  Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in ApcMin/+ mice.

Authors:  Kai Yang; Jie Zhu; Huan-Hua Luo; Shu-Wen Yu; Lu Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.